CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma
CYFRA 21-1 is a prognostic marker for non–small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-02-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428318760420 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839643702177300480 |
|---|---|
| author | Hiromichi Shirasu Akira Ono Katsuhiro Omae Kazuhisa Nakashima Shota Omori Kazushige Wakuda Hirotsugu Kenmotsu Tateaki Naito Haruyasu Murakami Masahiro Endo Takashi Nakajima Toshiaki Takahashi |
| author_facet | Hiromichi Shirasu Akira Ono Katsuhiro Omae Kazuhisa Nakashima Shota Omori Kazushige Wakuda Hirotsugu Kenmotsu Tateaki Naito Haruyasu Murakami Masahiro Endo Takashi Nakajima Toshiaki Takahashi |
| author_sort | Hiromichi Shirasu |
| collection | DOAJ |
| description | CYFRA 21-1 is a prognostic marker for non–small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung adenocarcinoma. Of the 79 patients who were treated with nivolumab therapy at the Shizuoka Cancer Center between December 2015 and September 2016, we retrospectively reviewed the data of 50 patients. The patient characteristics were as follows: age <70/≥70 years: 43 (86%)/7; male/female: 31 (62.0%)/19; Eastern Cooperative Oncology Group performance status 0–1/2: 43 (86%)/7; smoking status: no/yes: 18 (36%)/32; epidermal growth factor receptor mutation status negative/positive: 36 (72%)/14; CYFRA 21-1 ≥2.2/<2.2 ng/mL: 28 (56%)/22; carcinoembryonic antigen ≥5/<5 ng/mL: 29 (58%)/21; and number of prior regimens 2–3/≥4: 16 (32%)/34. With a median follow-up of 263.5 (range, 64–352) days, the median progression-free survival was 70 days. The clinical variables investigated using univariate analysis were as follows: age (p = 0.423), carcinoembryonic antigen (p = 0.888), epidermal growth factor receptor mutation status (p = 0.105), performance status (p = 0.968), sex (p = 0.210), number of prior regimens (p = 0.146), CYFRA 21-1 (p = 0.026), and smoking status (p = 0.041). A multivariate analysis identified a serum CYFRA 21-1 level ≥2.2 ng/mL as an independent predictor of a favorable outcome (hazard ratio, 0.44; 95% confidence interval, 0.23–0.85; p = 0.015; median progression-free survival, 155 vs 51.5 days). In conclusion, CYFRA 21-1 might be an independent predictor of outcome for patients with advanced lung adenocarcinoma treated with nivolumab. |
| format | Article |
| id | doaj-art-1a88b2cad8c4438abaed8a8e42f13033 |
| institution | Matheson Library |
| issn | 1423-0380 |
| language | English |
| publishDate | 2018-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-1a88b2cad8c4438abaed8a8e42f130332025-07-02T03:10:47ZengSAGE PublishingTumor Biology1423-03802018-02-014010.1177/1010428318760420CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinomaHiromichi Shirasu0Akira Ono1Katsuhiro Omae2Kazuhisa Nakashima3Shota Omori4Kazushige Wakuda5Hirotsugu Kenmotsu6Tateaki Naito7Haruyasu Murakami8Masahiro Endo9Takashi Nakajima10Toshiaki Takahashi11Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanDivision of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanClinical Research Promotion Unit, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanDivision of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanDivision of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanDivision of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanDivision of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanDivision of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanDivision of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanDivision of Diagnostic Radiology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanDivision of Diagnostic Pathology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanDivision of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, JapanCYFRA 21-1 is a prognostic marker for non–small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung adenocarcinoma. Of the 79 patients who were treated with nivolumab therapy at the Shizuoka Cancer Center between December 2015 and September 2016, we retrospectively reviewed the data of 50 patients. The patient characteristics were as follows: age <70/≥70 years: 43 (86%)/7; male/female: 31 (62.0%)/19; Eastern Cooperative Oncology Group performance status 0–1/2: 43 (86%)/7; smoking status: no/yes: 18 (36%)/32; epidermal growth factor receptor mutation status negative/positive: 36 (72%)/14; CYFRA 21-1 ≥2.2/<2.2 ng/mL: 28 (56%)/22; carcinoembryonic antigen ≥5/<5 ng/mL: 29 (58%)/21; and number of prior regimens 2–3/≥4: 16 (32%)/34. With a median follow-up of 263.5 (range, 64–352) days, the median progression-free survival was 70 days. The clinical variables investigated using univariate analysis were as follows: age (p = 0.423), carcinoembryonic antigen (p = 0.888), epidermal growth factor receptor mutation status (p = 0.105), performance status (p = 0.968), sex (p = 0.210), number of prior regimens (p = 0.146), CYFRA 21-1 (p = 0.026), and smoking status (p = 0.041). A multivariate analysis identified a serum CYFRA 21-1 level ≥2.2 ng/mL as an independent predictor of a favorable outcome (hazard ratio, 0.44; 95% confidence interval, 0.23–0.85; p = 0.015; median progression-free survival, 155 vs 51.5 days). In conclusion, CYFRA 21-1 might be an independent predictor of outcome for patients with advanced lung adenocarcinoma treated with nivolumab.https://doi.org/10.1177/1010428318760420 |
| spellingShingle | Hiromichi Shirasu Akira Ono Katsuhiro Omae Kazuhisa Nakashima Shota Omori Kazushige Wakuda Hirotsugu Kenmotsu Tateaki Naito Haruyasu Murakami Masahiro Endo Takashi Nakajima Toshiaki Takahashi CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma Tumor Biology |
| title | CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma |
| title_full | CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma |
| title_fullStr | CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma |
| title_full_unstemmed | CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma |
| title_short | CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma |
| title_sort | cyfra 21 1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma |
| url | https://doi.org/10.1177/1010428318760420 |
| work_keys_str_mv | AT hiromichishirasu cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT akiraono cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT katsuhiroomae cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT kazuhisanakashima cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT shotaomori cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT kazushigewakuda cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT hirotsugukenmotsu cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT tateakinaito cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT haruyasumurakami cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT masahiroendo cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT takashinakajima cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma AT toshiakitakahashi cyfra211predictstheefficacyofnivolumabinpatientswithadvancedlungadenocarcinoma |